"My laboratory has developed a number of new methods to look at changes in protein status within cells," said Professor Whetton. "We believe that the Cell Biosciences system will provide important new insights into the effect of leukaemogenic proteins on stem cell processes."
The Cell Biosciences platform is an ultrasensitive nanofluidic immunoassay system designed to analyze extremely small biological samples. Traditional protein analysis techniques can require as many as 100,000 cells, which complicates protein analysis in stem cells and other precious samples. Because of the Cell Biosciences system's high detection sensitivity, it can measure cell signaling proteins reproducibly in as few as 25 cells.
"The University of Manchester is an ideal location for our first UK placement," said Tim Harkness, President and Chief Executive Officer at Cell Biosciences. "We are pleased to see our products adopted by such a prestigious institution."
Cancer research in Manchester recently was rated best in the UK by the government-led Research Assessment Exercise (RAE), a comprehensive assessment of the quality of research at UK universities. The University of Manchester represents the second Cell Biosciences system sale in Europe.
About Cell Biosciences
Cell Biosciences is a private life sciences company focused on nanoproteomics. We develop instrumentation systems and assays for the measurement of phosphoprotein signaling and activation in extremely small biological samples. Our company's lead product is a capillary-based nanofluidic immunoassay platform that provides quantitative and reproducible data on key signaling pathways in precious biological samples, such as small tumor biopsies and stem cells. Cell Biosciences is located in Palo Alto, California.
www.cellbiosciences.com
info@cellbiosciences.com
